AUTHORS
Moniek de Dewitte, MD, PhD, Jarl Mooyaart2, Liesbeth de Wreede3, Raynier Devillier, PhD4, Peter Pal Remenyi5, Fabio Ciceri6, Lucia Prezioso7, Jan Vydra8, Antonio Pierini, MD, PhD9, Linde Morsink10, Franco Locatelli, MD PhD11, Mi Kwon , MD, PhD12, Marco Zecca13, Montserrat Rovira14, Alessandra Biffi, MD, PhD15, Jeroen Knippenberg16, Jorinde Hoogenboom17, Florent Malard, MD, PhD18, Simona Pagliuca19, Annalisa Ruggeri, MD20, Jurgen Kuball, MD21
AFFILIATIONS
1 University Medical Center Utrecht, Utrecht, Netherlands
2 EBMT Leiden Study Unit, Leiden, Netherlands
3 LUMC, Leiden, Netherlands
4 Insititut Paoli Calmettes, Marseille, France
5 Del-pesti Centrumkorhaz, Budapest, Hungary
6 IRCCS San Raffaele Hospital Scientific Institute, Milano, Italy
7 Hospital University of Parma, Parma, Italy
8 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
9 Sezione di Ematologia, Perugia, Italy
10 University Medical Center Groningen (UMCG), Rijks Universiteit Groningen (RUG), Groningen, Netherlands
11 IRRCS Ospedale Pediatrico Bambino Gesu, Catholic University of the Sacred Heart, Rome, Italy
12 Hospital General Universitario Gregorio Marañon, Madrid, Spain
13 San Matteo Pavia Transplant Programme, Pavia, Italy
14 Hospital Clinic, Barcelona, Spain
15 Padua University Hospital, Padova, Italy
16 EBMT Leiden Study Unit, Leiden, Netherlands
17 EBMT Leiden Study Unit, Leiden, Netherlands
18 Hôpital Saint Antoine, Paris, France
19 CHRU NANCY, Nancy, France
20 San Raffaele Scientific Institute, Milan, Italy
21 University Medical Center Utrecht, Utrecht, Netherlands
ABSTRACT
Background: Ex vivo αβ T-cell receptor (αβTCR)/CD19 depletion is increasingly used to reduce graft-versus-host disease (GvHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but has not yet been compared at scale with post-transplant cyclophosphamide (PTCy), one of the most widely used GvHD prophylaxis strategies. We compared outcomes between these two approaches using the EBMT registry.
Methods: In this retrospective registry study of the CTIWP of the EBMT, adult patients (≥18 years) undergoing a first allo-HCT for AML, ALL, MDS, or MPN between 2013 and 2021 who received either PTCy-based GvHD prophylaxis or an αβTCR/CD19-depleted graft were included. Patients receiving both PTCy and ATG were excluded. The primary endpoint was GvHD-free, relapse-free survival (GRFS). Secondary endpoints included acute and chronic GvHD, relapse, non-relapse mortality (NRM), relapse-free survival (RFS), and overall survival (OS). Kaplan-Meier and cumulative incidence analyses were used to assess unadjusted differences between the two strategies, whereas (cause-specific) Cox proportional hazards models were used to adjust for risk factors and potential confounders. Because of marked baseline imbalances, particularly in donor type and conditioning intensity, the complete cohort served as the primary analysis population, with a 1:1 propensity score-matched cohort (n = 214 per group) used as a sensitivity analysis.
Results: The PTCy cohort comprised 7,936 patients, and the αβTCR/CD19-depletion cohort comprised 225 patients. The median age was 56 years in both cohorts. Donor distributions differed between the cohorts: mismatched related donors, predominantly but not exclusively haploidentical, accounted for 59% of the PTCy cohort and 48% of the αβTCR/CD19-depletion cohort, whereas matched unrelated donors accounted for 17% and 33%, sibling donors for 13% and 11%, and 9/10 matched unrelated donors for 12% and 8%, respectively. AML was the most common diagnosis in both cohorts (52% and 43%, respectively), followed by MDS/MPN (26% and 30%) and ALL (22% and 27%). Standard-intensity conditioning was administered to 53% of patients in the PTCy cohort compared with 96% in the αβTCR/CD19-depletion cohort.
Compared with PTCy, αβTCR/CD19 depletion was associated with significantly lower cumulative incidences of grade II–IV acute GvHD (15.0% vs. 27.2%; p<0.0001), grade III–IV acute GvHD (5.2% vs. 9.7%; p=0.019), chronic GvHD of any grade (15.8% vs. 30.9%; p<0.001), and extensive chronic GvHD (2.7% vs. 12.8%; p<0.001) at 2 years. At 2 years, relapse (22.8% vs. 24.6%), NRM (20.5% vs. 21.2%), RFS (56.7% vs. 54.2%), and OS (62.8% vs. 60.4%) did not differ significantly between the groups. GRFS was higher with αβTCR/CD19 depletion in the unadjusted analysis (53.1% vs. 41.0%; p=0.007) but was no longer statistically significant after multivariable adjustment. αβTCR/CD19 depletion remained independently associated with a lower risk of grade II–IV acute GvHD (HR 0.46, 95% CI 0.26–0.83; p=0.01) and overall chronic GvHD (HR 0.43, 95% CI 0.22–0.84; p=0.014), with a similar trend for extensive chronic GvHD (HR 0.29, 95% CI 0.08–1.01; p=0.052). This protective effect on GvHD was most pronounced in patients transplanted for acute leukemia (AML: HR 0.38, p=0.022; ALL: HR 0.31, p=0.015), whereas no significant difference was observed in the smaller MDS/MPN subgroup (HR 1.09). In the propensity score-matched cohort, reductions in grade II–IV acute GvHD (15.2% vs. 21.9%; HR 0.51, p<0.001), chronic GvHD (15.6% vs. 35.0%; HR 0.43, p<0.001), and extensive chronic GvHD (2.9% vs. 11.8%; HR 0.21, p=0.002) were confirmed. Only the difference in grade III–IV acute GvHD lost statistical significance (5.4% vs. 7.8%; p=0.24). Relapse, NRM, RFS, and OS remained similar between the matched groups. Likewise, the difference in GRFS was no longer statistically significant (53.9% vs. 47.8%; p=0.47), consistent with the multivariable analysis.
Conclusions: In the largest comparison performed to date, αβTCR/CD19-depleted transplantation was associated with lower incidences of grade II–IV acute and chronic GvHD than PTCy. No statistically significant differences were observed in relapse, NRM, RFS, or OS, although the observational design does not permit conclusions regarding equivalence between the two platforms. These findings provide a strong rationale for prospective comparative evaluation.
DISCLOSURES
Moniek de Dewitte, MD, PhD: No relevant conflicts of interest to declare.